Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Bone marrow biopsy characteristics at nadir after intensive induction therapy do not predict outcomes in acute myeloid leukemia (AML): An analysis of ECOG-ACRIN clinical trials

Douglas Tremblay, Li Chen, Zhuoxin Sun, Chezi Ganzel, Hugo Fernandez, James Foran, Daniel Arber, Hillard Lazarus, Yanming Zhang, Elisabeth Paietta, John Bennett, Jacob Rowe, Mark Litzow, Martin Tallman, Ehab Atallah, Selina Luger

Blood (2025) 146 (Supplement 1): 871.

https://doi.org/10.1182/blood-2025-871

Published: 2025

Journal Articles

Inferior survival in black AML patients treated with intensive chemotherapy in ECOG-ACRIN clinical trials is independent of cytogenetic profiles

Shella Saint Fleur-Lominy, Li Chen, Zhuoxin Sun, Francine Garrett-Bakelman, Mihir Shukla, Hugo Fernandez, James Foran, Larry Cripe, Hillard Lazarus, Peter Wiernik, Jacob Rowe, Martin Tallman, Mark Litzow, Yanming Zhang, Selina Luger, Irum Khan

Blood (2025) 146 (Supplement 1): 290.

https://doi.org/10.1182/blood-2025-290

Published: 2025

Journal Articles

Genomic determinants of treatment outcome and identification of a new genomic subset of adult acute lymphoblastic leukemia from the ECOG-ACRIN E1910 randomized phase III trial

Blood (2025) 146 (Supplement 1): 31.

https://doi.org/10.1182/blood-2025-31

Published: 2025

Journal Articles

Prospective study of patient-reported depression, and cognitive and functional impairment, and impact on survival and induction mortality in fit adults age ≥60 years receiving intensive chemotherapy (IC) for Acute Myeloid Leukemia (AML): Prospective geriatric assessment (GA) report from ECOG-ACRIN (EA) E2906 randomized study

Blood (2025) 146 (Supplement 1): 882.

https://doi.org/10.1182/blood-2025-882

Published: 2025

Journal Articles

Sparse whole genome sequencing and machine learning of AML genomes reveals novel, clinically relevant genetics.

Blood (2025) 146 (Supplement 1): 5263.

https://doi.org/10.1182/blood-2025-5263

Published: 2025

Journal Articles

Subclinical cardiac changes following CPX-351 induction in adults with favorable/intermediate-risk AML

Chezi Ganzel, Avraham Frisch, Ofir Wolach, Yakir Moshe, Baher Krayem, Neta Dor, Jacob Rowe, Yishai Ofran

Blood (2025) 146 (Supplement 1): 5239.

https://doi.org/10.1182/blood-2025-5239

Published: 2025

Journal Articles

Impact of therapy delays on outcomes in adults with BCR::ABL1 negative b-lineage acute lymphoblastic leukemia (ALL) in the ECOG-ACRIN E1910 trial randomized to conventional chemotherapy +/- blinatumomab

Blood (2025) 146 (Supplement 1): 1549.

https://doi.org/10.1182/blood-2025-1549

Published: 2025

Journal Articles

Toxicities on the E1910 phase III randomized trial of blinatumomab plus chemotherapy in adults with BCR:ABL-1 negative acute lymphoblastic leukemia

Blood (2025) 146 (Supplement 1): 5120.

https://doi.org/10.1182/blood-2025-5120

Published: 2025

Journal Articles

Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis

Vikas Gupta, Sue Richards, Jacob Rowe

Blood (2013) 121 (2): 339–350.

https://doi.org/10.1182/blood-2012-07-445098

Published: 2013

Includes: Supplemental data

Journal Articles

WT1 mutations in T-ALL

Blood (2009) 114 (5): 1038–1045.

https://doi.org/10.1182/blood-2008-12-192039

Published: 2009

Includes: Supplemental data

Journal Articles

HLA-Identical Allogeneic Stem Cell Transplantation (alloSCT) for Patients with Primary Cutaneous T-Cell Lymphoma (CTCL): A Retrospective Analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (EBMT-LWP).

Rafael Duarte, Carme Canals, Francesco Onida, Eduardo Olavarria, William Arcese, Augustin Ferrant, Franco Narni, Andrea Bacigalupo, Donald Bunjes, Jacob Rowe, Giorgio Lambertenghi, Norbert Schmitz, Anna Sureda

Blood (2008) 112 (11): 1132.

https://doi.org/10.1182/blood.V112.11.1132.1132

Published: 2008

Journal Articles

Fusion Cell Vaccination in Conjunction with Stem Cell Transplantation Is Well Tolerated, Induces Anti-Tumor Immunity and Is Associated with Responses in Patients with Multiple Myeloma

Blood (2008) 112 (11): 826.

https://doi.org/10.1182/blood.V112.11.826.826

Published: 2008

Journal Articles

Induced CD4 + CD25 + FOXP-3 + and CD8+CD25 + FOXP-3 + t Cells Exhibit a Concurrent Expression of Effector and Selective Suppressive Capacities

Irit Avivi, MD, Dina Stroopinsky, Jacob Rowe, MD, David Avigan, MD, Tami Katz, Ph.D

Blood (2008) 112 (11): 3501.

https://doi.org/10.1182/blood.V112.11.3501.3501

Published: 2008

Journal Articles

A 3,239 -Patient Combined Eastern Cooperative Oncology Group (ECOG), M.D. Anderson Cancer Center (MDA) Analysis of the Effect of CR vs. Responses < CR on Long-Term Survival in Newly-Diagnosed AML Treated with Ara-C-Containing Regimens: Implications for Targeted Drug Development.

Elihu Estey, MD, Zhuoxin Sun, MD, Jacob Rowe, MD, Stefan Faderl, MD, Peter Cassileth, MD, George Sartiano, MD, Anthony Tartaglia, MD, Guillermo Garcia-Manero, MD, Larry Cripe, MD, John Bennett, MD, Hagop Kantarjian, MD, Martin Tallman, MD

Blood (2007) 110 (11): 298.

https://doi.org/10.1182/blood.V110.11.298.298

Published: 2007

Journal Articles

Phase III Trial of All-Trans Retinoic Acid (ATRA) vs Daunorubicin (D) and Cytosine Arabinoside (A) as Induction Therapy and ATRA vs Observation as Maintenance Therapy for Children with Newly Diagnosed Acute Promyelocytic Leukemia (APL).

John Gregory, MD, Haesook Kim, PhD, Todd Alonzo, MD, Rob Gerbing, PhD, Angela Ogden, MD, William Woods, MD, Howard Weinstein, MD, Lois Shepherd, MD, Charles Schiffer, MD, Frederick Appelbaum, MD, Cheryl Willman, MD, Peter Wiernik, MD, Jacob Rowe, MD, Martin Tallman, MD, James Feusner, MD

Blood (2005) 106 (11): 894.

https://doi.org/10.1182/blood.V106.11.894.894

Published: 2005

Journal Articles

Phase III Prospective Randomized Trial of EPO with or without G-CSF Versus Supportive Therapy Alone in the Treatment of Myelodysplastic Syndromes (MDS): Results of the ECOG- CLSG Trial(E1996).

Kenneth B. Miller, MD, Haesook T. Kim, PhD, Peter Greenberg, MD, Richard van der Jagt, MD, John M. Bennett, MD, Martin S. Tallman, MD, Elisabeth Paietta, PhD, Gordon Dewald, PhD, Jessie G. Houston, MD, Mary Thomas, RN, MS, Jacob Rowe, MD

Blood (2004) 104 (11): 70.

https://doi.org/10.1182/blood.V104.11.70.70

Published: 2004

Journal Articles

The Outcome of 551 1 st CR Transplants in Adult ALL from the UKALL XII/ECOG 2993 Study.

Anthony H. Goldstone, Hillard J. Lazarus, Sue M. Richards, Mark R. Litzow, Raj Chopra, Alan Burnett, Peter H. Wiernik, Ian M. Franklin, H. G. Prentice, Martin Tallman, G. Harrison, Jill Durrant, Jacob Rowe

Blood (2004) 104 (11): 615.

https://doi.org/10.1182/blood.V104.11.615.615

Published: 2004

Journal Articles

Impact of Cytogenetics on Outcome of Mismatched Unrelated Donor Hematopoietic Stem Cell Transplantation for Adults with AML.

Martin Tallman, Gordon Dewald, Hillard Lazarus, Sharavi Gandham, Gene Nelson, Brent Logan, Jacob Rowe, Mark Litzow, Armand Keating, Jayesh Mehta, Meir Wetzler, Tanya Warren, Daniel Weisdorf

Blood (2004) 104 (11): 830.

https://doi.org/10.1182/blood.V104.11.830.830

Published: 2004

Journal Articles

Improved Leukemia-Free Survival after Post-Consolidation Treatment with Histamine Dihydrochloride and Interleukin-2 in AML: A Randomized Phase III Trial.

Mats Brune, MD, Sylvie Castaigne, MD, John Catalano, MD, Kurt Gehlsen, PhD, Wolf-Karsten Hofmann, MD, Anthony Ho, MD, Donna Hogge, MD, Bo Nilsson, MD, Reuven Or, MD, Jacob Rowe, MD, Bengt Simonsson, MD, Ruth Spearing, MD, Edward Stadtmauer, MD, Jeff Szer, MD, Elisabeth Wallhult, RN, Kristoffer Hellstrand, MD

Blood (2004) 104 (11): 261.

https://doi.org/10.1182/blood.V104.11.261.261

Published: 2004

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Bone marrow biopsy characteristics at nadir after intensive induction therapy do not predict outcomes in acute myeloid leukemia (AML): An analysis of ECOG-ACRIN clinical trials

Inferior survival in black AML patients treated with intensive chemotherapy in ECOG-ACRIN clinical trials is independent of cytogenetic profiles

Genomic determinants of treatment outcome and identification of a new genomic subset of adult acute lymphoblastic leukemia from the ECOG-ACRIN E1910 randomized phase III trial

Sparse whole genome sequencing and machine learning of AML genomes reveals novel, clinically relevant genetics.

Subclinical cardiac changes following CPX-351 induction in adults with favorable/intermediate-risk AML

Impact of therapy delays on outcomes in adults with BCR::ABL1 negative b-lineage acute lymphoblastic leukemia (ALL) in the ECOG-ACRIN E1910 trial randomized to conventional chemotherapy +/- blinatumomab

Toxicities on the E1910 phase III randomized trial of blinatumomab plus chemotherapy in adults with BCR:ABL-1 negative acute lymphoblastic leukemia

Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis

WT1 mutations in T-ALL

HLA-Identical Allogeneic Stem Cell Transplantation (alloSCT) for Patients with Primary Cutaneous T-Cell Lymphoma (CTCL): A Retrospective Analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (EBMT-LWP).

Fusion Cell Vaccination in Conjunction with Stem Cell Transplantation Is Well Tolerated, Induces Anti-Tumor Immunity and Is Associated with Responses in Patients with Multiple Myeloma

Induced CD4 + CD25 + FOXP-3 + and CD8+CD25 + FOXP-3 + t Cells Exhibit a Concurrent Expression of Effector and Selective Suppressive Capacities

A 3,239 -Patient Combined Eastern Cooperative Oncology Group (ECOG), M.D. Anderson Cancer Center (MDA) Analysis of the Effect of CR vs. Responses < CR on Long-Term Survival in Newly-Diagnosed AML Treated with Ara-C-Containing Regimens: Implications for Targeted Drug Development.

Phase III Trial of All-Trans Retinoic Acid (ATRA) vs Daunorubicin (D) and Cytosine Arabinoside (A) as Induction Therapy and ATRA vs Observation as Maintenance Therapy for Children with Newly Diagnosed Acute Promyelocytic Leukemia (APL).

Phase III Prospective Randomized Trial of EPO with or without G-CSF Versus Supportive Therapy Alone in the Treatment of Myelodysplastic Syndromes (MDS): Results of the ECOG- CLSG Trial(E1996).

The Outcome of 551 1 st CR Transplants in Adult ALL from the UKALL XII/ECOG 2993 Study.

Impact of Cytogenetics on Outcome of Mismatched Unrelated Donor Hematopoietic Stem Cell Transplantation for Adults with AML.

Improved Leukemia-Free Survival after Post-Consolidation Treatment with Histamine Dihydrochloride and Interleukin-2 in AML: A Randomized Phase III Trial.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only